Arctoris and Evariste Technologies form a joint venture to identify novel small lolecule cMET Inhibitors for non-small cell lung cancer
Arctoris, a tech-enabled biopharma company, and Evariste Technologies, an AI-drug discovery company, have formed a joint venture to identify novel small molecule kinase inhibitors for treatment of patients with Non-Small Cell Lung Cancer (NSCLC).